Viveretx
Berkeley, US · Founded 2022 · 1 known investors
Vivere is an early-stage biotech developing cancer therapies that use a bioengineering platform (based on UC Berkeley research) to activate the immune system against "cold" solid tumors through targeted delivery. It focuses on immuno-oncology and gene/viral vector engineering to treat difficult solid cancers.
BiotechDeep TechHealthtech
Founders & leadership
Viveretx was founded in 2022 by Adam Schieferecke, Hyuncheol Lee, David Schaffer, John Dueber, and Wanichaya Noiwangklang.
AS
Adam SchiefereckeCo-founder; Head of Research
HL
Hyuncheol LeeCo-founder; Head of Nonclinical Development
DS
David SchafferinCo-founder; PresidentExecutive Director of QB3, Director of Bakar Labs at Berkeley Frontier
JD
John DueberCo-founder; Scientific Advisor
WN
Wanichaya NoiwangklangCo-founder; Head of Operations
Investors · 1
Frequently asked questions
- What does Viveretx do?
- Vivere is an early-stage biotech developing cancer therapies that use a bioengineering platform (based on UC Berkeley research) to activate the immune system against "cold" solid tumors through targeted delivery. It focuses on immuno-oncology and gene/viral vector engineering to treat difficult solid cancers.
- Who founded Viveretx?
- Viveretx was founded by Adam Schieferecke, Hyuncheol Lee, David Schaffer, John Dueber, Wanichaya Noiwangklang in 2022.
- Who are Viveretx's investors?
- Viveretx's investors include Berkeley Frontier.
- Where is Viveretx headquartered?
- Viveretx is headquartered in Berkeley, US.